How should a pulmonary embolism (PE) that occurred three days after a microdiscectomy be classified and managed, given the patient previously had an unprovoked pulmonary embolism (PE) during severe COVID‑19 infection?

Classification and Management of Post-Microdiscectomy Pulmonary Embolism

Classification: Surgery-Provoked PE

This PE should be classified as surgery-provoked because it occurred within 3 days of microdiscectomy, which is a major transient risk factor that supersedes the patient's prior unprovoked COVID-19-associated PE. 1

The European Society of Cardiology defines provoked PE as an event associated with a major transient or reversible risk factor such as surgery, trauma, or immobilization. 1 Surgery within the preceding 4 weeks is universally recognized as a major provoking factor. 1 Although this patient had a prior unprovoked PE during severe COVID-19, the temporal relationship to recent surgery (3 days) makes the current event surgery-provoked. 1

Immediate Management

Risk Stratification and Initial Anticoagulation

• Immediately assess hemodynamic stability (shock, systolic BP < 90 mmHg, cardiac arrest) to identify high-risk PE requiring urgent reperfusion therapy. 1
• Start therapeutic anticoagulation without delay while diagnostic work-up proceeds if clinical probability is high or intermediate. 1
• For hemodynamically stable patients, prefer low-molecular-weight heparin (LMWH) or fondaparinux over unfractionated heparin (UFH). 1
• Reserve UFH for hemodynamically unstable patients or those with severe renal impairment (creatinine clearance < 30 mL/min). 1

Thrombolysis Decision

• Administer systemic thrombolytic therapy immediately only if the patient presents with shock, persistent hypotension, or cardiac arrest (high-risk PE) and has no high bleeding risk. 1
• Do not use systemic thrombolysis in hemodynamically stable (intermediate- or low-risk) PE, even in the early post-operative period, because bleeding risk outweighs benefit. 1
• Surgical pulmonary embolectomy is indicated when thrombolysis is absolutely contraindicated (recent surgery is a relative contraindication) or fails to improve hemodynamics within one hour. 1

Oral Anticoagulation Selection

• Transition to a direct oral anticoagulant (NOAC)—rivaroxaban 15 mg twice daily for 21 days then 20 mg daily, or apixaban 10 mg twice daily for 7 days then 5 mg twice daily—once the patient is hemodynamically stable and has no contraindications. 1
• NOACs are preferred over warfarin because they do not require parenteral overlap and simplify outpatient management. 1
• Avoid NOACs if creatinine clearance is < 25–30 mL/min or if the patient has antiphospholipid antibody syndrome; use warfarin (target INR 2.0–3.0) instead. 1

Duration of Anticoagulation: 3 Months Only

Because this PE is surgery-provoked, discontinue anticoagulation after exactly 3 months; the annual recurrence risk after stopping is < 1% and does not justify indefinite therapy. 1, 2

The European Society of Cardiology explicitly states that provoked PE (associated with major transient/reversible risk factors such as surgery) should be treated for 3 months only. 1, 2 Extending anticoagulation beyond 3 months in provoked PE provides no benefit and increases bleeding risk. 1, 2

Why the Prior Unprovoked COVID-19 PE Does Not Change Duration

• The prior PE during severe COVID-19 infection is considered provoked by the acute viral illness, not unprovoked. 3, 4, 5
• COVID-19 induces a hypercoagulable state through endothelial activation, inflammation, and direct vascular injury, making it a transient provoking factor. 4, 5, 6
• Research demonstrates that COVID-19-associated PE has distinct pathophysiology from conventional unprovoked PE, including in situ pulmonary thrombosis and thromboinflammation. 4, 5, 6
• The 2026 AHA/ACC guideline recognizes COVID-19 as a provoking factor for VTE. 7
• Even if the prior COVID-19 PE were considered unprovoked, the current surgery-provoked event resets the classification; the most recent provoking factor determines duration. 1

Mandatory Follow-Up

• Schedule a clinical review at 3 months to confirm resolution of symptoms, assess for persistent dyspnea (possible chronic thromboembolic pulmonary hypertension), and discontinue anticoagulation. 1, 2
• If dyspnea or functional limitation persists at 3 months, perform ventilation-perfusion (V/Q) scintigraphy to detect mismatched perfusion defects suggestive of CTEPH. 1
• Refer symptomatic patients with persistent perfusion defects to a pulmonary hypertension/CTEPH expert center. 1

Critical Pitfalls to Avoid

• Do not extend anticoagulation beyond 3 months in surgery-provoked PE; the low recurrence risk (< 1% annually) does not outweigh bleeding risk. 1, 2
• Do not classify this PE as unprovoked based solely on the prior COVID-19 PE history; the temporal relationship to surgery is the dominant factor. 1
• Do not use NOACs in severe renal impairment (< 25–30 mL/min) or antiphospholipid syndrome; warfarin is mandatory. 1
• Do not delay anticoagulation while awaiting diagnostic confirmation if clinical probability is high or intermediate. 1
• Do not place an inferior vena cava (IVC) filter routinely; filters are reserved only for patients with absolute contraindications to anticoagulation (e.g., active major bleeding). 1